Paclitaxel remains first-line for cutaneous angiosarcoma, but absence of validated second-line therapy creates a major unmet ...

The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma. Although immunotherapy has become a mainstay of ...

“[...] PHA is a rare yet aggressive mesenchymal tumor of the liver, which requires a multi-disciplinary approach to achieve the best patient outcomes.” “In our ...

PAX3/7-FOXO1 fusions by fluorescent in situ hybridization (FISH) using an adult rhabdomyosarcoma tissue microarray. Background: Surgical management of cutaneous angiosarcoma (AS) of the head and neck ...

Angiosarcoma is an aggressive malignancy derived from endothelial cells, characterised by its rapid progression, heterogeneity and distinct clinical challenges. As a subset of soft tissue sarcomas, ...

Two rare presentations and treatments of Ewing's sarcoma: A need for a standard treatment approach. Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and ...

Seven years after completing breast cancer treatment, Angelia Carpenter was shocked to discover she had angiosarcoma, a rare cancer that may have been associated with her breast cancer treatment. When ...

Angiosarcoma of the gastrointestinal tract is an exceedingly rare and aggressive vascular tumour that arises from the endothelial cells lining blood vessels. Although primary angiosarcoma in this ...